



**GlaxoSmithKline
Supplier Diversity
5 Moore Drive
PO Box 13398
Durham, NC 27709-3398**

Tel. 919.315.3781
Fax: 336.369.8974
www.gsk.com

VIA ELECTRONIC MAIL (AGO.highcostprescriptiondrugs@vermont.gov)

August 24, 2020

Office of The Attorney General
State of Vermont
Attn: TJ Donovan, Attorney General
109 State Street
Montpelier, VT 05609

RE: Notice of New Prescription Drug Pursuant to 18 V.S.A §4637(b)

Dear Mr. Donovan:

GlaxoSmithKline ("GSK") is issuing this notice pursuant to 18 V.S.A §4637(b) to inform you that on August 21, 2020 GSK introduced a new prescription drug to market (in the U.S. and Vermont) at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program.

The new drug, listed below with its respective NDC, is:

- (1) BLENREP, BLENREP INJ 100 MG (NDC: 00173089601)

Please let me know if you have any questions about this notice or the products referenced herein.

Kind regards,

Jennifer Smith
Pricing Operations Manager
Payer Marketing
US

Email Jennifer.3.smith@gsk.com